A new approach to the molecule you know and trust.
Globally, an estimated 65 million people have epilepsy, and 1 billion suffer from migraine. In the United States, 1 in 26 people will develop epilepsy during their lifetime, and approximately 39 million suffer from migraine.1,2
Antiepileptic drugs (AEDs) are the most commonly used treatment for epilepsy.
But what do patients who struggle with existing AED formulations do?
And how do HCPs treat patients who cannot take pills, especially children and patients with dysphagia?
When prescribed AEDs are available only in capsule or pill form, HCPs and patients are often forced into work-around situations, like crushing pills, dissolving capsule contents, or obtaining a liquid formulation through a compounding pharmacy. Unfortunately, compounded drugs are not FDA approved.
Beyond convenience and quality for patients and caregivers, HCPs desire improved dosing and titration flexibility and the opportunity to tailor dose adjustments by patient circumstance.
The goal was to reach pediatric neurologists, neurologists, nurse practitioners, and epileptologists who believe a more tailored approach could benefit their patients. Additionally, we wanted to drive awareness for Azurity’s EPRONTIA by communicating that this liquid formulation may provide the tailored approach they need by encompassing consistency, dosing customization, reliability, and convenient administration.
A new approach to the molecule you know and trust.
We developed a campaign that delivers a powerfully simple idea—that through technology and innovation, medication can be transformed to cater to each patient’s needs, with a tailored approach and a proven therapy.
Our creative approach visually showcases how EPRONTIA has transformed how patients are given their medication. During market research, HCPs and patients connected emotionally with our butterfly breaking free from the cocoon/pill. Not only is the butterfly stunning, but the essence and beauty behind the transformation into an easy-to-take, visually appealing formulation provided inspirational stopping power.
The simple yet dynamic tagline for EPRONTIA’s concept hit home. “Medication Transformed” signals the potential impact of this medication on patients’ lives and the transformative nature of this new approach. The ready-to-use liquid formulation of EPRONTIA provides a treatment that addresses a significant unmet medical need for patients, caregivers, and the HCPs who treat them.
With our work on EPRONTIA, we are proud to support Azurity in its vision to transform the lives of patients and caregivers living with seizures or migraine.
1. Epilepsy Foundation. What is epilepsy? Accessed June7, 2022. https://www.epilepsy.com/what-is-epilepsy 2. American Migraine Foundation. Navigating life with a migraine. Accessed June 7, 2022. https://americanmigrainefoundation.org/living-with-migraine/migraine-essentials/